Cures, jobs, ethics on the line in vote on stem cell research
By Megha Satyanarayana,
Detroit Free Press
| 09. 24. 2008
Opposing sides dig in as vote nears on Proposal 2
Ryan Dinkgrave lived a carefree life in Livonia until he was diagnosed with type I diabetes at age 10. Suddenly everything was ordered and careful.
"It makes you rethink everything you do," he said. "You're young, you're told you need to do shots, you're measuring your blood sugar. You have to count, carefully measure everything you eat."
Dinkgrave, now 25 and of Royal Oak, is among Michigan residents who support Proposal 2, a November ballot initiative allowing Michigan researchers to make embryonic stem cell cultures from excess embryos donated from fertility treatments. Researchers say the cells could unlock the secrets of disease and lead to cures for illnesses such as Alzheimer's and type I diabetes.
Voters will decide this emotionally charged issue on the basis of a 100-word ballot initiative -- one that could not only affect people's health, but also the economy of Michigan for decades to come. Proponents say the measure could spark a life sciences sector and pump billions of dollars into the state's struggling economy.
Opponents insist embryonic stem cell research is unnecessary because alternative types...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...